TAZVERIK (tazemetostat)

Tazemetostat is a first-in-class EZH2 inhibitor approved for advanced epithelioid sarcoma and certain R/R FL patients. Now available in China, it restores tumor suppressor gene expression to control tumor growth.

Relma-cel (Carteyva) Receives NMPA Approval for in Relapsed or Refractory Follicular Lymphoma

China expands CAR-T treatment options as relma-cel (Carteyva®) receives NMPA approval for relapsed or refractory follicular lymphoma, demonstrating high response rates in clinical trials.